GLP-1 agonists: A review for emergency clinicians.
Long B, Pelletier J, Koyfman A, Bridwell RE.
Long B, et al. Among authors: koyfman a.
Am J Emerg Med. 2024 Apr;78:89-94. doi: 10.1016/j.ajem.2024.01.010. Epub 2024 Jan 12.
Am J Emerg Med. 2024.
PMID: 38241775
Review.
The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) and liraglutide (Saxenda, approved for weight loss, and Victoza, approved for type 2 diabetes), though an oral formulation of semaglutide is a …
The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) an …